中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
NASH
Cancer Lipid Metabolism and Oral Checkpoint Inhibitors
Viral Hepatitis/HIV/AIDS
Pipeline & Products
Pipeline
Products
Clinical Trials
Partnership
Investors
Financials & Filing
Presentation Materials
News
Careers
2021
2020
2019
2018
2017
2016
2015
2014
First Subject Dosed with Gannex’s FXR Agonist ASC42 in a U.S. Phase I Trial
2020-12-28
Overweight and Obese Subjects Dosed with ASC41 Tablets in a Phase Ib Trial
2020-12-22
Gannex Received U.S. FDA Fast Track Designation for Its NASH Drug Candidate ASC42,an FXR Agonist
2020-12-14
Subcutaneously Administered PD-L1 Antibody ASC22 (Envafolimab) is Safe and Well Tolerated in Phase IIa HBV Study
2020-12-03
Gannex Appoints Former Takeda Head of Liver Disease Clinical Development Melissa Palmer, MD as Chief Medical Officer
2020-11-30
1
2
3
4
»